• Dtsch. Med. Wochenschr. · Mar 2024

    [Rheumatoid arthritis: Appraisement of the new security warnings for JAK-inhibitors].

    • Christoph Fiehn.
    • Klinische Immunologie, Rheumatologie Baden-Baden, Baden-Baden.
    • Dtsch. Med. Wochenschr. 2024 Mar 1; 149 (6): 326330326-330.

    AbstractJanuskinase-Inhibitors (JAKI) are highly effective substances (JAKi) for the treatment of rheumatoid arthritis (RA). In terms of efficiency in reduction of disease activity and induction of remission they are partially prior to biologic (b) DMARDs. Presently the four substances tofacitinib, baricitinib, upadacitinib and filgotinib are approved for the treatment of RA. The prospective controlled ORAL-SURVEILLANCE-trial investigated the safety of tofacitinib in comparison to TNF-inhibitors. Current results now show that treatment with tofacitinib might be associated with an increased risk for cardiovascular events, thromboembolism and certain malignancies. Affected are patients >65y, current or former smoker and, regarding cardiovascular events, patients who already had such an event. On the basis of this trial the Committee for Medical Products for Human Use (CHMP) of the European Medicines Agency (EMA) formulated actual recommendations for prescription of JAKi in order to reduce the risk of severe undesirable effects. These apply not only for tofacitinib but as well for all other JAKI named above, as a class effect was supposed. The data and their consequences are discussed and evaluated in this work.Thieme. All rights reserved.

      Pubmed     Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…